This study is looking at atopic dermatitis, a skin condition that causes red, itchy, and inflamed skin. The study is for people who have moderate to severe forms of this condition, meaning their symptoms are more than mild and affect larger areas of their body. People in the study must have had this skin condition for at least one year before joining. The study will test a medication called GIA632, which is given as an injection under the skin. Some people in the study will receive GIA632 while others will receive placebo. The purpose of the study is to see how well GIA632 works compared to placebo at week 16.
The study will last for 16 weeks of treatment. During this time, participants will visit the study site regularly so doctors can check their skin condition and overall health. The doctors will use a scoring system to measure how clear the skin becomes during treatment. They will look for people whose skin becomes clear or almost clear with at least a 2 point improvement from when they started the study. The study will also carefully watch for any unwanted effects that might happen during treatment and after the study ends.
Participants must be adults who are 18 years of age or older. Their atopic dermatitis must be diagnosed according to specific medical criteria and must be at a moderate to severe level at both the first visit and when treatment starts. The study is designed so that neither the participants nor the doctors know who is receiving the actual medication and who is receiving placebo during the treatment period. This helps ensure the results are measured fairly and accurately.
Bulgaria 
Czechia 
France 
Germany 
Poland 
